Littérature scientifique sur le sujet « Genetically engineered drugs »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Genetically engineered drugs ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Genetically engineered drugs"
Jones-Grizzle, Amy J., et J. Lyle Bootman. « Pharmacoeconomics of Genetically Engineered Drugs ». PharmacoEconomics 1, no 1 (janvier 1992) : 45–53. http://dx.doi.org/10.2165/00019053-199201010-00009.
Texte intégralKishore, Kamal, et Pawan Krishan. « Pharmacology of recombinant or genetically engineered drugs ». Journal of Young Pharmacists 1, no 2 (2009) : 141. http://dx.doi.org/10.4103/0975-1483.55747.
Texte intégralKhobeysh, M. M., et E. V. Sokolovskiy. « Genetically engineered biologics to treat psoriasis. Experience with ustekinumab in an adolescent with severe psoriasis ». Meditsinskiy sovet = Medical Council, no 1 (12 mars 2023) : 123–29. http://dx.doi.org/10.21518/ms2023-003.
Texte intégralМатюнова, Алла, Alla Matyunova, Людмила Брегель et Lyudmila Bregel. « MODERN JUVENILE IDIOPATHIC ARTHRITIS THERAPY OF WITH THE USE OF BIOLOGICAL MEDICATIONS IN A REGIONAL CHILDREN”S 3 LEVEL HOSPITAL - RESULTS AND PROBLEMS ». Acta biomedica scientifica 2, no 5 (18 janvier 2018) : 102–6. http://dx.doi.org/10.12737/article_5a3a0e4744a0a8.88140750.
Texte intégralHuang, Ya Qiong, Kenneth L. White, De Shun Shi, Xu Jian Chen, Jia Zhou Li, Shi Yuan Zeng, Shi Hua Zhao et Gui Wen Ruan. « Development and Prospect of Genetically Engineered Pharmaceutics ». Advanced Materials Research 746 (août 2013) : 588–92. http://dx.doi.org/10.4028/www.scientific.net/amr.746.588.
Texte intégralZyryanov, S. K., et O. I. Butranova. « Genetically engineered drugs for treatment of bronchial asthma : recent achievements ». Russian Pulmonology 28, no 5 (24 décembre 2018) : 584–601. http://dx.doi.org/10.18093/0869-0189-2018-28-5-584-601.
Texte intégralLeonova, K. « Selected problems in the use of genetic engineering biological therapy in patients with rheumatoid arthritis ». Clinical Medicine and Pharmacology 6, no 4 (2 février 2021) : 36–39. http://dx.doi.org/10.12737/2409-3750-2021-6-4-36-39.
Texte intégralAvdeev, Sergey N., Alexandr V. Emelyanov, Oksana M. Kurbacheva, Irina M. Marusenko, Pavel I. Novikov, Olga A. Rizakhanova et Larisa V. Shul’zhenko. « A new delivery device for benralizumab (autoinjector, pen-injector device) in the clinical practice of treating severe eosinophilic asthma : Conclusion of the Expert Council ». PULMONOLOGIYA 31, no 6 (16 décembre 2021) : 776–81. http://dx.doi.org/10.18093/0869-0189-2021-31-6-776-781.
Texte intégralCho, Kyungjoo, Simon Weonsang Ro, Sang Hyun Seo, Youjin Jeon, Hyuk Moon, Do Young Kim et Seung Up Kim. « Genetically Engineered Mouse Models for Liver Cancer ». Cancers 12, no 1 (19 décembre 2019) : 14. http://dx.doi.org/10.3390/cancers12010014.
Texte intégralSamigullina, R. R., V. I. Mazurov et E. A. Trofimov. « Characteristics of complex therapy of immuno-inflammatory rheumatic diseases in COVID-19 pandemic conditions ». Russian Medical Inquiry 5, no 5 (2021) : 260–67. http://dx.doi.org/10.32364/2587-6821-2021-5-5-260-267.
Texte intégralThèses sur le sujet "Genetically engineered drugs"
Mustafa, Suhad As'ad. « The development of genetically engineered bacterial enzymes as sensor biological recognition elements for the detection of drugs and explosives ». Thesis, Bangor University, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.540409.
Texte intégralCreedon, Helen. « Use of genetically engineered mouse models in preclinical drug development ». Thesis, University of Edinburgh, 2015. http://hdl.handle.net/1842/15911.
Texte intégralGning, Fatima. « Construction d’une usine pharmaceutique : impératifs réglementaires, sécuritaires et de rentabilité ». Electronic Thesis or Diss., Université Paris-Panthéon-Assas, 2022. http://www.theses.fr/2022ASSA0078.
Texte intégralThe pharmaceutical industry is continually confronted with major changes that constantly redefine the balance between the protection of public health and the economic development strategies of pharmaceutical companies. The drug market is the terrain of major economic challenges for France and increasing its global market share remains a major concern. The achievement of this objective seems to be done around a first axis relating to the development of genetic engineering. The second axis concerns the construction of new production plants on a national and international scale in order to increase its production capacities. However, the construction of new pharmaceutical factories intended to design, manufacture and then market drugs for human use is proving difficult due to the combination of pharmaceutical law, an esoteric matter by nature, and construction law, which abounds in subjects that are eminently techniques. Added to this is its purpose, which is to ensure and preserve the health of the patient throughout the life cycle of the drug, to innovate, to increase production capacities, while meeting the highest manufacturing standards. Such an initiative is all the more daring in a geopolitical context strongly weakened by the 2020 pandemic and then the Russo-Ukrainian conflict which exacerbated the shortage and the extension of supply times for many raw materials, caused a historic increase their cost and, in fact, the overall cost of carrying out construction projects
Jung, Lin Wan, et 林婉蓉. « Safety and Quality Regulation of Biomedicine in Taiwan and China : Focus on Genetically Engineered Drug ». Thesis, 2015. http://ndltd.ncl.edu.tw/handle/24410564380688915598.
Texte intégral國立清華大學
科技法律研究所
103
As the problems of safety and drug tolerance of chemicals get ever more serious, the market of biomedicine grows rapidly to make up for the deficiencies of chemicals in remedial areas. Regulations in Taiwan and China and applications thereof which shall be followed through different stages when promoting genetic engineered medicine into market are discussed in this thesis. Since genetic engineered medicine is categorized as one sort of biomedicine, it should be in accordance with the rules set for biomedicine first and be further considered if regulations targeted to genetic engineered medicine exist. Taiwan and China mainly impose the control of toxicity measurement regarding the rules of content in nonclinical test. Taiwan has further related regulations before entering into nonclinical test, while China does not. The procedural regulations of nonclinical test in Taiwan is mainly stipulated in Good Laboratory Practice, and for China in Good Laboratory Practice (the translation is the same but it is different in Chinese). In Taiwan, Major Review items in Clinical trials of pharmaceuticals is set as the corresponsive rules before biomedicine goes under human clinical test. While in China, Veterinary Drugs Control Act and its Enforcement Statute for are the corresponsive rules thereon. The regulatory framework in Taiwan during clinical test is referred to Good Clinical Practice, and that in China is Good Clinical Practice (the translation is the same but it is different in Chinese). Finally, to ensure the safety of drug usage and increase the quality of medicine, Taiwan and China both make corresponsive regulations in accordance with the International standard of GMP (Good Manufactured Practice). After comparing with the regulations from both countries, it can be found that Taiwan mainly focuses on PIC/S: Guide to Good Manufacturing Practice for Medicinal Products while China concentrates in Good Manufacture Practice of Drugs.
Livres sur le sujet "Genetically engineered drugs"
Copsey, David N., et Sabine Y. J. Delnatte. Genetically Engineered Human Therapeutic Drugs. London : Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09800-2.
Texte intégralN, Copsey David, et Delnatte Sabine Y. J, dir. Genetically engineered human therapeutic drugs. New York, N.Y : Stockton Press, 1988.
Trouver le texte intégralDictionary of Genetically Engineered Human Therapeutic Drugs. Pan Macmillan, 1988.
Trouver le texte intégralGOVERNMENT, US. 21st Century Complete Guide to Biotechnology : Federal Research and Regulation, Bioengineered and Genetically Modified (GM) Crops, Seeds, Foods, and Drugs, Genetically Engineered Organisms, Agricultural Biotechnology (DVD-ROM). Progressive Management, 2005.
Trouver le texte intégralUS GOVERNMENT. 2005 Biotechnology Encyclopedia : Federal Research and Regulation, Bioengineered and Genetically Modified (GM) Crops, Seeds, Foods, and Drugs, Genetically Engineered (GE) Organisms, Agricultural Biotechnology, FDA, USDA, EPA, NIH, DOE (DVD-ROM). Progressive Management, 2005.
Trouver le texte intégralUS GOVERNMENT. 21st Century Essential Guide to Genetic Engineering and Biotechnology : Federal Research and Regulation, Bioengineered and Genetically Modified (GM) Crops, Seeds, Foods, and Drugs, Genetically Engineered (GE) Organisms, Agricultural Biotechnology, FDA, USDA, EPA, NIH, DOE (DVD-ROM). Progressive Management, 2005.
Trouver le texte intégralBates, Gillian P., et Christian Landles. Preclinical Experimental Therapeutics. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199929146.003.0016.
Texte intégralChapitres de livres sur le sujet "Genetically engineered drugs"
Hentschel, Christopher. « Overview : Recombinant DNA Proteins and Drug Discovery ». Dans Genetically Engineered Human Therapeutic Drugs, 3–6. London : Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09800-2_1.
Texte intégralBalkwill, Frances R. « Cytokines in Cancer Therapy ». Dans Genetically Engineered Human Therapeutic Drugs, 6–9. London : Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09800-2_2.
Texte intégralDuff, Gordon W., Julian A. Symons et Francesco S. Di Giovine. « Recombinant DNA Proteins and Prospects for Treatment of Inflammatory Diseases ». Dans Genetically Engineered Human Therapeutic Drugs, 9–13. London : Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09800-2_3.
Texte intégralTuddenham, Edward. « Cardiovascular and Blood-Related Proteins ». Dans Genetically Engineered Human Therapeutic Drugs, 14–16. London : Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09800-2_4.
Texte intégralGordon, Sarah L. « Overview of Commercial Prospects for Biotechnology Products in Health Care ». Dans Genetically Engineered Human Therapeutic Drugs, 137–42. London : Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09800-2_5.
Texte intégralGillies, Stephen D. « Designing immunocytokines : genetically engineered fusion proteins for targeted immune therapy ». Dans Recombinant Protein Drugs, 129–47. Basel : Birkhäuser Basel, 2001. http://dx.doi.org/10.1007/978-3-0348-8346-7_6.
Texte intégralSacca, Rosalba, Sandra J. Engle, Wenning Qin, Jeffrey L. Stock et John D. McNeish. « Genetically Engineered Mouse Models in Drug Discovery Research ». Dans Methods in Molecular Biology, 37–54. Totowa, NJ : Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60761-058-8_3.
Texte intégralCarbajal, Eletha, et Eric C. Holland. « Mouse Models in Preclinical Drug Development : Applications to CNS Models ». Dans Genetically Engineered Mice for Cancer Research, 549–67. New York, NY : Springer New York, 2011. http://dx.doi.org/10.1007/978-0-387-69805-2_26.
Texte intégralLoeber, Gerhard, et Renate Schnitzer. « The use of Genetically Engineered Cells in Drug Discovery ». Dans Genetic Engineering, 249–66. Boston, MA : Springer US, 1998. http://dx.doi.org/10.1007/978-1-4899-1739-3_13.
Texte intégralFloyd, Warren, Hsuan-Cheng Kuo, Jonathon E. Himes, Rutulkumar Patel et David G. Kirsch. « Genetically Engineered Mouse Models for Studying Radiation Biology and Radiosensitizers ». Dans Cancer Drug Discovery and Development, 161–90. Cham : Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-49701-9_8.
Texte intégralActes de conférences sur le sujet "Genetically engineered drugs"
Aksenova, Valentina, Nadezda Klevno, Elena Dementjeva et Alexey Kazakov. « TB infection in children receiving genetically engineered biologic drugs ». Dans ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa3626.
Texte intégralToner, Mehmet. « Moving Living Cells and Fluids on Microchips for Diagnostics ». Dans ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-192786.
Texte intégralSilva, Maísa de Carvalho, Lariza Laura De Oliveira et Renato Tinós. « Optimization of Expanded Genetic Codes via Genetic Algorithms ». Dans XV Encontro Nacional de Inteligência Artificial e Computacional. Sociedade Brasileira de Computação - SBC, 2018. http://dx.doi.org/10.5753/eniac.2018.4440.
Texte intégralSharpless, Norman E. « Abstract CN03-01 : Drug testing in genetically engineered murine models. » Dans Abstracts : AACR-NCI-EORTC International Conference : Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013 ; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-cn03-01.
Texte intégralQiu, Weiguo, Joseph Cappello et Xiaoyi Wu. « Fabrication of Genetically Engineered Silk-Elastin-Like Protein Polymer Fibers ». Dans ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-190980.
Texte intégralTeng, Weibing, Joseph Cappello et Xiaoyi Wu. « Viscoelastic Properties of Genetically Engineered Silk-Elastin-Like Protein Polymers ». Dans ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-192252.
Texte intégralLowe, Scott W. « Abstract PL01-03 : Drug resistance and tumor maintenance in genetically engineered mice ». Dans Abstracts : AACR-NCI-EORTC International Conference : Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009 ; Boston, MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/1535-7163.targ-09-pl01-03.
Texte intégralSeidel, Diana, Anastasia Shibina, C. Patrick Reynolds, Winfried S. Wels, Nicole Huebener et Holger N. Lode. « Abstract 2808 : GD2-specific genetically engineered NK cell therapy is effective in a drug-resistant neuroblastoma xenograft mouse model ». Dans Proceedings : AACR Annual Meeting 2014 ; April 5-9, 2014 ; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-2808.
Texte intégralLee, Edmund Chun Yu, Michael Fitzgerald, Bret Bannerman, Jennifer Terkelsen, Ray Liu, Zhi Li, Mark Manfredi et al. « Abstract 397 : The antitumor activity of the investigational drug MLN9708 in genetically engineered mouse models of plasma cell malignancy ». Dans Proceedings : AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010 ; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-397.
Texte intégralCuppoletti, John. « Composite Synthetic Membranes Containing Native and Engineered Transport Proteins ». Dans ASME 2008 Conference on Smart Materials, Adaptive Structures and Intelligent Systems. ASMEDC, 2008. http://dx.doi.org/10.1115/smasis2008-449.
Texte intégral